Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 3.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 723,705 shares of the medical technology company’s stock after buying an additional 24,421 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Stryker were worth $251,980,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker during the 3rd quarter worth $34,000. Copia Wealth Management increased its stake in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 69 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Stryker during the 4th quarter worth $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Stock Performance
NYSE:SYK opened at $295.39 on Wednesday. Stryker Corporation has a 1 year low of $290.17 and a 1 year high of $404.87. The firm’s fifty day simple moving average is $343.97 and its 200 day simple moving average is $356.28. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $113.13 billion, a PE ratio of 34.19, a PEG ratio of 1.72 and a beta of 0.80.
Analyst Ratings Changes
Several research analysts have recently commented on SYK shares. Needham & Company LLC dropped their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday. Leerink Partners initiated coverage on shares of Stryker in a research note on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $395.48.
Get Our Latest Research Report on Stryker
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
